SPARC Is associated with gastric cancer progression and poor survival of patients

Clinical Cancer Research

Volumn 16, Issue 1, 2010, Pages 260-268

  Zhao, Zhong Sheng ^a   Wang, Yuan Yu ^a   Chu, Yong Quan ^a   Ye, Zai Yuan ^a   Tao, Hou Quan ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; GELATINASE A; OSTEONECTIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; SURVIVAL RATE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD29; DISEASE PROGRESSION; FEMALE; GASTRIC MUCOSA; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM METASTASIS; OSTEONECTIN; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 74949109359     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1247     Document Type: Article

References (37)

1. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005;81:419-24.
2. Zhan W, Han F. Surgical therapy of gastric cancer in china. J Pract Oncol 2008;23:91-3.
3. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10:49-58.
4. Qi Y, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999;47:1495-505.
5. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002;14:608-16.
6. Menon PM, Gutierrez JA, Rempel SA. A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin. Int J Oncol 2000;17:683-93.
7. Iacobuzio-Donahue CA, Argani P, Hempen PM, et al. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 2002;62:5351-7.
8. Yamashita K, Upadhay S, Mimori K, et al. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003;97:2412-9.
9. Thomas R, True LD, Bassuk JA, et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-9.
10. Yamanaka M, Kanda K, Li NC, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001;166:2495-9.
11. Takano T, Hasegawa Y, Matsuzuka F, et al. Gene expression profiles in thyroid carcinomas. Br J Cancer 2000;83:1495-502.
12. Maeng HY, Song SB, Choi DK, et al. Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Lett 2002;184:117-21.
13. Wang C-S, Lin K-H, Chen S-L, et al. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004;91:1924-30.
14. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001;19:816-27.
15. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 1994;8:163-73.
16. McClung HM, Thomas SL, Osenkowski P, et al. SPARC up-regulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 2007;419:172-7.
17. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin β1 and activation of integrin-linked kinase. J Biol Chem 2008;283:22826-37.
18. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.
19. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001;92:1427-34.
20. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003;16:79-84.
21. Lee HS, Cho SB, Lee HE, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 2007;13:4154-63.
22. Kolev Y, Uetake H, Iida S, et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 2007;14:2738-47.
23. Mizokami K, Kakeji Y, Oda S, et al. Clinicopathologic significance of hypoxia-inducible factor 1 α overexpression in gastric carcinomas. J Surg Oncol 2006;94:149-54.
24. Song LB, Liao WT, Mai HQ, et al. The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett 2006;242:258-65.
25. Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002;8:3445-53.
26. Fukuoka J, Fujii T, Shih JH, et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 2004;10:4314-24.
27. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004;92:679-90.
28. Podhajcer OL, Benedetti L, Girotti MR, et al. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:523-37.
29. Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC(osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-72.
30. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-25.
31. He Q, Chen J, Lin HL, et al. Expression of peroxisome proliferator-activated receptor γ, E-cadherin and matrix metalloproteinases-2 in gastric carcinoma and lymph node metastases. Chin Med J Engl 2007;120:1498-504.
32. Wang LB, Jiang ZN, Fan MY, et al. Changes of histology and expression of MMP-2 and nm23-1 in primary and metastatic gastric cancer. World J Gastroenterol 2008;14:1612-6.
33. Mönig SP, Baldus SE, Hennecken JK, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001;39:597-602.
34. Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006;26:3579-83.
35. Alakus H, Grass G, Hennecken JK, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 2008;23:917-23.
36. Matsuoka T, Yashiro M, Nishimura S, et al. Increased expression of α2β1-integrin in the peritoneal dissemination of human gastric carcinoma. Int J Mol Med 2000;5:21-5.
37. Yoshimasu T, Sakurai T, Oura S, et al. Increased expression of integrin α3β1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 2004;95:142-8.